New clinical evidence of the advantages of lithotripsy treatment of benign prostatic hyperplasia (BPH) using MOSES™ Technology is being presented at the American Urological Association's (AUA) annual meeting, taking place in Chicago, May 3-6, 2019.
Terra Venture Partners, established almost a decade ago as a cleantech investment fund, invests in companies from a range of industries with a positive impact on society, including in agriculture, construction, manufacturing, transportation and healthcare.
The reverse split will take effect tomorrow, April 1. As a result of the reverse share split, every twenty-five ordinary shares of ReWalk issued and outstanding were automatically combined and reclassified into one ordinary share of ReWalk. Appropriate adjustments were also made to all outstanding derivative securities of the Company, including all outstanding equity awards and warrants.
to Deliver the Industry’s Best File-sharing Capabilities with Integrated SMB Protocol for OEMs Through Better Interoperability Between Windows and Non-Windows Machines
NVIDIA and Mellanox just announced that NVIDIA has agreed to a cash purchase of all issued and outstanding common stock at a price of $125/share.
This version includes a number of new features: internal packet capture including IPv6, DNS and Netbios traffic, an enhanced mount command, and an enhanced directory lookup with pattern matching.
The Israel Innovation Authority and Startup Nation Central recently released the Human Capital Survey Report 2018. You can download it here.
Watch CEO & Founder of EyeCue, Ronen Horovitz discuss their "Do It Yourself" 3D scanning with Yoni Kempinski of Arutz Sheva.
Mr. Ahrens joins Mellanox from GlobalLogic, where he served as CFO . Prior to that he served as CFO of Applied Micro Circuits.
The treatment is given with a device small butterfly-shaped stent, which lifts the prostate's lobes and supports them so that they do not squeeze the urethra and cause it to narrow. The device, developed by Butterfly Medical, does not meet the urinary fluid and therefore does not expose patients to the risk of infection and stones. The patients who received the treatment reported that they did not feel the implant and did not experience any pain.